Cartesian Therapeutics Amends 8-K, Updates HQ Address
Ticker: RNAC · Form: 8-K/A · Filed: Jan 23, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative-update, corporate-governance, address-change
TL;DR
**Cartesian Therapeutics just updated its HQ address in an 8-K/A, signaling a potential operational shift.**
AI Summary
Cartesian Therapeutics, Inc. filed an 8-K/A on January 23, 2024, amending its original 8-K from November 13, 2023. This amendment primarily updates the company's principal executive offices from 65 Grove Street, Watertown, MA to 704 Quince Orchard Road, Gaithersburg, Maryland 20878. This matters to investors because a change in headquarters can signal strategic shifts, operational restructuring, or a move closer to key talent or resources, potentially impacting future performance and investor confidence.
Why It Matters
A change in headquarters can indicate a strategic shift, operational restructuring, or a move to a more advantageous location, which could affect the company's future operations and expenses.
Risk Assessment
Risk Level: low — This filing is an administrative update regarding a change of address and does not inherently present significant financial or operational risks.
Analyst Insight
Investors should note the change in headquarters as a potential indicator of strategic or operational shifts, but this filing alone doesn't provide enough information for a definitive investment decision. Further investigation into the reasons behind the move might be warranted.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — the registrant filing the 8-K/A
- 704 Quince Orchard Road, Gaithersburg, Maryland 20878 (address) — new principal executive offices
- 65 Grove Street, Watertown, MA 02472 (address) — former principal executive offices
- November 13, 2023 (date) — date of earliest event reported in the original 8-K
- January 23, 2024 (date) — filing date of the 8-K/A
FAQ
What is the primary purpose of this 8-K/A filing by Cartesian Therapeutics, Inc.?
The primary purpose of this 8-K/A filing is to amend the original 8-K filed on November 13, 2023, specifically to update the registrant's principal executive offices from 65 Grove Street, Watertown, MA to 704 Quince Orchard Road, Gaithersburg, Maryland 20878.
When was the earliest event reported in the original 8-K that this amendment refers to?
The earliest event reported in the original 8-K, as stated in the filing, was November 13, 2023.
What is the new address for Cartesian Therapeutics, Inc.'s principal executive offices?
The new address for Cartesian Therapeutics, Inc.'s principal executive offices is 704 Quince Orchard Road, Gaithersburg, Maryland 20878.
What was the previous address for Cartesian Therapeutics, Inc.'s principal executive offices?
The previous address for Cartesian Therapeutics, Inc.'s principal executive offices was 65 Grove Street, Watertown, MA 02472.
Is Cartesian Therapeutics, Inc. considered an emerging growth company according to this filing?
Yes, the filing indicates with a checked box that Cartesian Therapeutics, Inc. is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-01-23 16:05:34
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC
Filing Documents
- ny20014884x4_8ka.htm (8-K/A) — 33KB
- ny20014884x4_ex23-1.htm (EX-23.1) — 2KB
- ny20014884x4_ex99-1.htm (EX-99.1) — 356KB
- ny20014884x4_ex99-2.htm (EX-99.2) — 280KB
- ny20014884x4_ex99-3.htm (EX-99.3) — 491KB
- 0001140361-24-003407.txt ( ) — 1390KB
- selb-20231113.xsd (EX-101.SCH) — 4KB
- selb-20231113_lab.xml (EX-101.LAB) — 22KB
- selb-20231113_pre.xml (EX-101.PRE) — 16KB
- ny20014884x4_8ka_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a)
Financial statements of businesses acquired
Financial statements of businesses acquired. The audited financial statements and accompanying notes of Old Cartesian as of and for the years ended December 31, 2022 and 2021 are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference . The unaudited financial statements and accompanying notes of Old Cartesian as of and for the nine months ended September 30, 2023 and 2022 are filed as Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated herein by reference. (b) Pro forma financial information. The unaudited pro forma condensed combined balance sheet as of September 30, 2023, the unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2023, the unaudited pro forma combined statement of operations for the year ended December 31, 2022, and the related notes of Cartesian Therapeutics, Inc. with respect to the transaction described above, are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and incorporated herein by reference. (d) Exhibits. Exhibit Number Description 23.1 Consent of BDO USA, P.C. 99.1 Audited financial statements of Old Cartesian, as of December 31, 2022 and 2021 and for the years then ended. 99.2 Unaudited financial statements of Old Cartesian, as of and for the nine months ended September 30, 2023 and 2022. 99.3 Unaudited pro forma condensed combined financial information of Cartesian Therapeutics, Inc. with respect to the acquisition of Old Cartesian. 104 Cover Page Interactive Data File (formatted as inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 23, 2024 CARTESIAN THERAPEUTICS, INC. By: /s/ Carsten Brunn, Ph.D. Name: Carsten Brunn, Ph.D. Title: President and Chief Executive Officer